Zhang Longyu,Sun Ying,Huang Ang,et al.. Role of nucleotide-binding and oligomerization domain-like receptors P3 inflammasome in patients with alcoholic liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 678-682.
[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 酒精性肝病诊疗指南. 中华肝脏病杂志,2010,18(3):167-171. [2] 王晓霞,李保森. 2002 至2011 年中国“北方”地区住院肝硬化患者病因构成及变化趋势分析. 实用肝脏病杂志,2014,17(2):154-158. [3] 邹正升,王晓霞. 住院的酒精性肝病患者临床疾病特点分析. 实用肝脏病杂志,2014,17(1):26-29. [4] Martinon F,Burns K,Tschopp J,et al. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell,2002,10(2):417-426. [5] Akira S US,Takeuch I. Pathogen recognition and innateimmunity. Cell,2006,124(4):783-801. [6] Tschopp J. NALPs:a novel protein family involved in inflammation. Nat Rev Mol Cell Biol,2003,4(2):95-104. [7] Cassel SL,Joly S,Sutterwala FS,et al. The NLRP3 inflammasome:a sensor of immune danger signals. Semin Immunol,2009,21(4):194-198. [8] Albano E,Vidali M. Immune mechanisms in alcoholic liver disease. Genes Nutr,2010,5:141-147. [9] Szabo G,Csak T. Inflammasomes in liver diseases. J Hepatol,2012,57(3):642-654. [10] Gross O,Thomas CJ,Guarda G,et al. The inflammasome:an integrated view. Immunol Rev,2011,243(1):136-151. [11] Szabo G,Petrasek J. Inflammasome activation and function in liver disease. Nature Rev Gastroenterol Hepatol,2015,12:387-400. [12] Lippai D,Bala S,Petrasek J,et al. Alcohol-induced IL-1 in the brain is mediated by NLRP3/ASC inflammasome activation that amplifies neuroinflammation. J Leukoc Biol,2013,94:171-182.、 [13] Ayna G,Krysko DV,Kaczmarek A,et al. ATP release from dying autophagic cells and their phagocytosis are crucial for inflamma- some activation in macrophages. PLoS One,2012,7(6):e40069. [14] Zhou1 R,Yazdi1 AS,Menu1 P,et al. A role for mitochondria in NLRP3 inflammasome activation. Nature,2011,469:221-226. [15] Petrasek J,Bala S,Csak T,et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest,2012,122(10):3476-3489. [16] Peng Y,French BA,Tillman B,et al. The inflammasome in alcoholic hepatitis:Its relationship with Mallory-Denk body formation. Exp Mol Pathol,2014,97(2):305-313. [17] Larsen CM,Faulenbach M,Vaag A,et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. Medication,2007,356:1517-1526. [18] McGonagle D,Tan AL,Madden J,et al. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum,2008,58(2):631-633. [19] So A,De Smedt T,Revaz S,et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther,2007,9(2):R28. [20] Bauernfeind F,Ablasser A,Bartok E,et al. Inflammasomes:current understanding and open questions. Cell Mol Life Sci,2011,68(5):765-783.